Bioventus expands hyaluronic acid product for osteoarthritis into Australia, New Zealand

Alan Condon -   Print  |
Listen

Bioventus plans to expand Durolane, its hyaluronic acid joint-fluid osteoarthritis injection, into Australia and New Zealand.

Four things to know:

1. Durolane is used in the symptomatic treatment of mild to moderate hip osteoarthritis and mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers and toes.

2. The orthobiologic company is also launching another HA-based product, Durolane SJ, in both countries later this year.

3. Durolane SJ is used in the symptomatic treatment of mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers and toes.

4. Both products are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within three months of the operation.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers